Floatz logo

Luspatercept

Anemia

Guangdong Second Provincial General Hospitalprotein_peptidePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Anemia cohort.

Asset / SponsorPhaseRating
Epoetin Alfa
Mayo Clinic
Phase 4BBB
Erythropoietin Human Recombinant
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Epoetin Beta
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BBB
Darbepoetin Alfa
Amgen
Phase 3BBB

View all 50 →

Same molecule, other indications

Luspatercept is also rated in:

beta-thalassemia majorDormant
BB
Indicative ·
65 / 100
View asset →
beta thalassemiaDormant
BB
Indicative ·
64 / 100
View asset →
myelofibrosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →